■ Sight Sciences reported a new, single-center study of glaucoma surgery patients published in Clinical Ophthalmology, which shows that ab-interno microcatheterization and 360˚ viscodilation of Schlemm’s canal using one of the OMNI Surgical System’s predicate devices (VISCO360) provides a favorable safety profile and substantial long-term reductions in both IOP and IOP-lowering medications. The study was a retrospective analysis of 106 eyes from 71 consecutive patients with mild to moderate primary open-angle glaucoma treated with the VISCO360 in combination with cataract surgery at Eye Center Cologne in Germany.

The study found 41% IOP reduction (24.6 mmHg to 14.6 mmHg) at 12 months in eyes with a baseline pressure of 18 mmHg or more. Eighty-six percent of all eyes were medication free at 12 months. The most common adverse event was hyphema (13% of eyes). In all cases, hyphema resolved within 7 days without any intervention. GP